<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:38:04Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2938114" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2938114</identifier><datestamp>2010-09-17</datestamp><setSpec>mcp</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mol Cell Proteomics</journal-id>
      <journal-id journal-id-type="hwp">mcprot</journal-id>
      <journal-id journal-id-type="pmc">mcprot</journal-id>
      <journal-id journal-id-type="publisher-id">MCP</journal-id>
      <journal-title-group>
        <journal-title>Molecular &amp; Cellular Proteomics : MCP</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1535-9476</issn>
      <issn pub-type="epub">1535-9484</issn>
      <publisher>
        <publisher-name>The American Society for Biochemistry and Molecular Biology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2938114</article-id>
      <article-id pub-id-type="pmcid">PMC2938114</article-id>
      <article-id pub-id-type="pmc-uid">2938114</article-id>
      <article-id pub-id-type="pmid">20551380</article-id>
      <article-id pub-id-type="pmid">20551380</article-id>
      <article-id pub-id-type="publisher-id">M110.001693</article-id>
      <article-id pub-id-type="doi">10.1074/mcp.M110.001693</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Proteomics Characterization of Extracellular Space Components in the Human Aorta<xref ref-type="fn" rid="FN1">*</xref><xref ref-type="fn" rid="FN2"><sup><inline-graphic xlink:href="sbox.jpg"/></sup></xref></article-title>
        <alt-title alt-title-type="short">Proteomics of Vascular Extracellular Matrix</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Didangelos</surname>
            <given-names>Athanasios</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">â¡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yin</surname>
            <given-names>Xiaoke</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">â¡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mandal</surname>
            <given-names>Kaushik</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">Â§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baumert</surname>
            <given-names>Mark</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">Â¶</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jahangiri</surname>
            <given-names>Marjan</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">â</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mayr</surname>
            <given-names>Manuel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">â¡</xref>
          <xref ref-type="corresp" rid="cor1">**</xref>
        </contrib>
        <aff id="aff1">From the â¡King's British Heart Foundation Centre, King's College, London SE5 9NU, United Kingdom, </aff>
        <aff id="aff2">Â§Department of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, </aff>
        <aff id="aff3">Â¶Advion BioSciences, Harlow CM20 2NQ United Kingdom, </aff>
        <aff id="aff4">âDepartment of Cardiac Surgery, St. George's Healthcare National Health Service Trust, London SW17 0QT, United Kingdom</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">** Supported by a senior research fellowship from the British Heart Foundation. To whom correspondence should be addressed:
<addr-line>Cardiovascular Division, King's British Heart Foundation Centre, King's College London School of Medicine, King's College London, 125 Coldharbour Lane, London SE5 9NU, UK.</addr-line> Tel.:
<phone>44-20-7848-5238</phone>; E-mail: <email>manuel.mayr@kcl.ac.uk</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>6</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>15</day>
        <month>6</month>
        <year>2010</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
      <volume>9</volume>
      <issue>9</issue>
      <fpage>2048</fpage>
      <lpage>2062</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>6</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2010 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
        <license license-type="open-access">
          <license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non-Commercial License</ext-link> applies to Author Choice Articles</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zjw00910002048.pdf"/>
      <abstract>
        <p>The vascular extracellular matrix (ECM) is essential for the structural integrity of the vessel wall and also serves as a substrate for the binding and retention of secreted products of vascular cells as well as molecules coming from the circulation. Although proteomics has been previously applied to vascular tissues, few studies have specifically targeted the vascular ECM and its associated proteins. Thus, its detailed composition remains to be characterized. In this study, we describe a methodology for the extraction of extracellular proteins from human aortas and their identification by proteomics. The approach is based on (<italic>a</italic>) effective decellularization to enrich for scarce extracellular proteins, (<italic>b</italic>) successful solubilization and deglycosylation of ECM proteins, and (<italic>c</italic>) relative estimation of protein abundance using spectral counting. Our three-step extraction approach resulted in the identification of 103 extracellular proteins of which one-third have never been reported in the proteomics literature of vascular tissues. In particular, three glycoproteins (podocan, sclerostin, and agrin) were identified for the first time in human aortas at the protein level. We also identified extracellular adipocyte enhancer-binding protein 1, the cartilage glycoprotein asporin, and a previously hypothetical protein, retinal pigment epithelium (RPE) spondin. Moreover, our methodology allowed us to screen for proteolysis in the aortic samples based on the identification of proteolytic enzymes and their corresponding degradation products. For instance, we were able to detect matrix metalloproteinase-9 by mass spectrometry and relate its presence to degradation of fibronectin in a clinical specimen. We expect this proteomics methodology to further our understanding of the composition of the vascular extracellular environment, shed light on ECM remodeling and degradation, and provide insights into important pathological processes, such as plaque rupture, aneurysm formation, and restenosis.</p>
      </abstract>
    </article-meta>
  </front>
  <body><p>Vascular cells, in particular vascular smooth muscle cells, produce and maintain a complex meshwork of ECM.<xref ref-type="fn" rid="G1"><sup>1</sup></xref> The ECM is not only the scaffold for the anchorage and mobility of residing cells but also absorbs and transduces the shear and strain forces of the blood flow. It is primarily composed of elastin, collagen, proteoglycans, and glycoproteins. The elastin fibers and type I and III fibrillar collagens form a rigid network of highly cross-linked interstitial matrix. They offer elasticity (elastin) and tensile strength (collagens). Proteoglycans, because of their negative charge, attract water and confer resistance to compression. Finally, glycoproteins participate in matrix organization and are essential for cell attachment.</p><p>The vascular ECM also serves as a substrate for the binding and retention of secreted, soluble proteins of vascular cells as well as molecules coming from the circulation, including lipoproteins, growth factors, cytokines, proteases, and protease inhibitors. These components are invariably associated with ECM proteins, especially proteoglycans. Together they comprise the vascular extracellular environment and are pivotal for disease processes, such as atherosclerosis and aneurysm formation (<xref ref-type="bibr" rid="B1">1</xref>).</p><p>Although proteomics has been previously applied to vascular tissues, only one study has specifically targeted the extracellular vascular environment (<xref ref-type="bibr" rid="B2">2</xref>). This study was focused on the isolation of intimal proteoglycans from human carotid arteries. Moreover, most proteomics studies use whole tissue lysates, which are rich in cellular proteins that inevitably mask the identification of the less abundant proteins of the vascular extracellular environment (<xref ref-type="bibr" rid="B3">3</xref><xref ref-type="bibr" rid="B4"/>â<xref ref-type="bibr" rid="B5">5</xref>). Thus, the composition of the vascular ECM and its associated proteins remains poorly defined. In the present study, we used morphologically normal human aortic samples to develop a method for the extraction of proteins present in the extracellular environment, including ECM proteins and proteins attached to the ECM. We had three specific aims: first, to reduce the contamination with cellular proteins, thereby increasing the chance of identifying scarce extracellular proteins; second, to efficiently solubilize and deglycosylate ECM proteins to improve their analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS); and third, to interface the nanoflow LC system to a recently developed injection device, which splits the flow from the analytical column, to allow the reanalysis of the same sample during a single LC-MS/MS run (RePlay, Advion).</p><p>Our methodology provides a detailed overview of the aortic ECM and its associated proteins, many reported for the first time in proteomics analysis of the vasculature. Most importantly, this method could be adapted for use with other tissues to further our understanding of the composition of extracellular environment and ECM turnover under various disease conditions.</p><sec sec-type="methods"><title>EXPERIMENTAL PROCEDURES</title><sec><title/><sec><title/><sec><title>Tissue Processing, Decellularization, and Extraction of Extracellular Space Proteins</title><p>The data presented were derived from three human aortic samples. The samples were obtained upon aortotomy performed during routine aortic valve replacement. They were collected from positions of the ascending aorta that were free of macroscopically evident vascular pathology, including atherosclerosis or aneurysm formation. The tissue was immediately snap frozen and subsequently kept in liquid nitrogen for later use. A fourth sample was also obtained upon aortotomy and processed as described below, but the proteomics analysis revealed proteolysis of ECM proteins. Therefore, we used it to examine the potential of our methodology to study proteolytic activity in the tissue. All procedures were approved by our local Regional Ethics Committee Board. Informed consent was obtained from all patients recruited into the study.</p><p>Before extraction, the tissue pieces were partially thawed and weighed. Approximately 150 mg of tissue per aortic sample were immediately placed in ice-cold phosphate-buffered saline to remove plasma contaminants. Commercially available protease and phosphatase inhibitor mixtures (Sigma-Aldrich) were included according to the manufacturer's instructions to inhibit broad range proteinase activity, and 25 m<sc>m</sc> EDTA was included to ensure inhibition of metalloproteinases. While the tissue samples were immersed in the cold saline mixture, they were quickly diced with a scalpel into 8â10 smaller pieces. This would enhance (<italic>a</italic>) the initial removal of plasma contaminants and (<italic>b</italic>) the effective extraction of extracellular proteins, which is described below. The saline mixture was changed five times (â¼30 ml total per sample).</p><p>Then, the diced samples were incubated with 0.5 <sc>m</sc> NaCl, 10 m<sc>m</sc> Tris, pH 7.5 supplemented with proteinase/phosphatase inhibitor mixtures (Sigma-Aldrich) and 25 m<sc>m</sc> EDTA. The volume of the buffer was adjusted to 10:1 of the tissue weight (<italic>i.e.</italic> 100 mg in 1 ml), and the samples were mildly vortexed for 4 h at room temperature. The NaCl extracts were then desalted with centrifugation using desalting columns (Zeba Spin, Pierce). Following desalting, the extracts were mixed with 100% acetone (5:1 volume ratio) at â20 Â°C for 16 h. Proteins were precipitated with centrifugation (16,000 Ã <italic>g</italic> for 45 min), and the pellets were dried and redissolved in deglycosylation buffer (see below).</p><p>Subsequently, the aortic samples were incubated with 0.08% SDS (10:1 buffer volume to tissue weight) supplemented with proteinase/phosphatase inhibitor mixtures and 25 m<sc>m</sc> EDTA. The samples were mildly vortexed for 4 h at room temperature to achieve removal of cellular components. From our experience with tissue extractions, we took particular care to ensure a low vortexing speed to decrease the possibility of mechanical disruption of the ECM. The SDS solution was then removed and stored frozen for later use.</p><p>Finally, the samples were incubated in a 4 <sc>m</sc> guanidine HCl, 50 m<sc>m</sc> sodium acetate, pH 5.8 buffer (5:1 buffer volume to tissue weight) supplemented with proteinase/phosphatase inhibitor mixtures and 25 m<sc>m</sc> EDTA. Adjusting the pH to 5.8 is important; more than 30 years ago it was shown that at this pH guanidine is more effective in solubilizing vascular proteoglycans, whereas higher pH is required for the solubilization of the proteoglycans from other ECM-rich tissues, such as cartilage (<xref ref-type="bibr" rid="B6">6</xref>). The samples were then incubated for 48 h at room temperature and vortexed vigorously to enhance mechanical disruption of the ECM components. Subsequently, the guanidine extracts were mixed with 100% ethanol (5:1 volume ratio) at â20 Â°C for 16 h to ensure removal of guanidine (the presence of guanidine would hinder further biochemical processing). Proteins were precipitated with centrifugation (16,000 Ã <italic>g</italic> for 45 min), and the pellets were washed with 90% ethanol, dried, and redissolved in deglycosylation buffer (see below).</p><p>Deglycosylation (removal of glycosaminoglycan side chains) of the different extracts was achieved in a 150 m<sc>m</sc> NaCl, 50 m<sc>m</sc> sodium acetate, pH 6.8 buffer supplemented with proteinase/phosphatase inhibitors and 10 m<sc>m</sc> EDTA for 16 h at 37 Â°C. The deglycosylation enzymes (0.05 unit) used were chondroitinase ABC from <italic>Proteus vulgaris</italic> (It catalyzes the removal of polysaccharides containing 1â4-Î²-<sc>d</sc>-hexosaminyl and 1â3-Î²-<sc>d</sc>-glucuronosyl or 1â3-Î±-<sc>l</sc>-iduronosyl linkages to disaccharides containing 4-deoxy-Î²-<sc>d</sc>-gluc-4-enuronosyl groups. It acts on chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate glycosaminoglycan side chains.), keratanase from <italic>Bacteroides fragilis</italic> (cleaves internal 1â4-Î²-galactose linkages in unbranched, repeating poly-<italic>N</italic>-acetyl-lactosamine and keratan sulfate), and heparitinase II from <italic>Flavobacterium heparinum</italic> (cleaves heparan sulfate), all purchased from Sigma-Aldrich. Following deglycosylation, the solutions were clarified again with centrifugation (16,000 Ã <italic>g</italic> for 10 min) to ensure that the samples were free of turbidity, and protein concentration was estimated by UV absorbance at 280 nm using extinction coefficient of 1.1 of 0.1% mg/ml solution calculated on the basis of the frequency of tyrosine and tryptophan, which are the main UV light-absorbing amino acids at 280 nm in mammalian proteins (<xref ref-type="bibr" rid="B7">7</xref>).</p></sec><sec><title>One-dimensional Electrophoresis</title><p>The NaCl, guanidine, and SDS extracts were denatured and reduced in sample buffer containing 100 m<sc>m</sc> Tris, pH 6.8, 40% glycerol, 0.2% SDS, 2% Î²-mercaptoethanol, and 0.02% bromphenol blue and boiled at 96 Â°C for 10 min. 35 Î¼g of protein per sample were loaded and separated on Bis-Tris discontinuous 4â12% polyacrylamide gradient gels (NuPAGE, Invitrogen). Prestained protein standards were run alongside the samples to allow molecular mass estimation of proteins (All Blue, Precision Plus, Bio-Rad).</p></sec><sec><title>Nanoflow LC-MS/MS for NaCl and Guanidine Extracts</title><p>After electrophoresis, gels were stained using the PlusOne Silver staining kit (GE Healthcare). Silver staining was used for band excision to avoid cross-contamination with fainter gel bands. (Coomassie staining will predominantly stain the abundant proteins; hence, fainter gel bands could be missed.). The gel bands were excised in identical parallel positions across lanes, and no âemptyâ gel pieces were left behind. Subsequently, all gel bands were subjected to in-gel digestion with trypsin using an Investigator ProGest (Genomic Solutions) robotic digestion system. Tryptic peptides from the NaCl and guanidine extracts were separated on a nanoflow LC system (Dionex UltiMate 3000) and eluted with a 40-min gradient (10â25% B in 35 min, 25â40% B in 5 min, 90% B in 10 min, and 2% B in 30min where A is 2% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O and B is 90% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O). The column (Dionex PepMap C<sub>18</sub>, 25-cm length, 75-Î¼m internal diameter, 3-Î¼m particle size) was coupled to a nanospray source (Picoview) using RePlay (Advion). After the direct LC-MS run, the flow was switched, and the portion stored in the capillary of the RePlay device was reanalyzed (âreplay runâ) (<xref ref-type="bibr" rid="B8">8</xref>). Spectra were collected from an ion trap mass analyzer (LTQ-Orbitrap XL, Thermo Fisher Scientific) using full ion scan mode over the mass-to-charge (<italic>m</italic>/<italic>z</italic>) range 450â1600. MS/MS was performed on the top six ions in each MS scan using the data-dependent acquisition mode with dynamic exclusion enabled. MS/MS peak lists were generated by extract_msn.exe and matched to a human database (UniProtKB/Swiss-Prot Release 14.6, 20,333 protein entries) using SEQUEST version 28 (revision 13) (Bioworks Browser 3.3.1 SP1, Thermo Fisher Scientific) and X! Tandem (version 2007.01.01.2). Carboxyamidomethylation of cysteine was chosen as a fixed modification, and oxidation of methionine was chosen as a variable modification. The mass tolerance was set at 1.5 amu for the precursor ions and at 1.0 amu for fragment ions. Two missed cleavages were allowed. Scaffold (version 2.0.5, Proteome Software Inc., Portland, OR) was used to calculate the spectral counts and to validate MS/MS-based peptide and protein identifications (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). According to the default values in the Scaffold software, the following peptide thresholds were applied: X! Tandem: âlog(Expect scores) &gt; 2.0; SEQUEST: ÎCn &gt; 0.10 and XCorr &gt; 2.5 (2+), 3.5 (3+), and 3.5 (4+). Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm (<xref ref-type="bibr" rid="B9">9</xref>). Protein identifications were accepted if they could be established at greater than 99.0% probability (<xref ref-type="bibr" rid="B10">10</xref>) with at least two independent peptides and a precursor ion mass accuracy â¤10 ppm.</p></sec><sec><title>Nanoflow LC-MS/MS for SDS Extracts</title><p>The protein concentration in the SDS extracts was estimated using the Groves equation, (<italic>A</italic><sub>280</sub> Ã 1.55) â (<italic>A</italic><sub>260</sub> Ã 0.76) (<xref ref-type="bibr" rid="B11">11</xref>), which takes into account nucleic acid interference. 35 Î¼g of protein per sample were loaded and separated on Bis-Tris discontinuous 4â12% polyacrylamide gradient gels as above. The gel was silver-stained, and protein bands were digested by trypsin as described above. Tryptic peptides were separated on a split-free, nanoflow LC system (EASY-nLC, Proxeon) on a C<sub>18</sub> column (Easy-nLC C<sub>18</sub>, Proxeon, 10-cm length, 75-Î¼m internal diameter, 3-Î¼m particle size) and eluted with an 80-min gradient (10â25% B in 35 min, 25â40% B in 5 min, 90% B in 10 min, and 2% B in 30min where A is 2% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O and B is 90% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O). The nanoflow LC system was not coupled to a RePlay device. Spectra were collected from a dual pressure, linear ion trap (LTQ Velos, Thermo Fisher Scientific) using full ion scan mode over the <italic>m</italic>/<italic>z</italic> range 300â1800. MS/MS was performed on the top 20 ions in each MS scan using the data-dependent acquisition mode with dynamic exclusion enabled. MS/MS peak lists were generated by extract_msn.exe and matched to a human database (UniProtKB/Swiss-Prot Release 15.13, 20,276 protein entries) using SEQUEST version 28 (revision 13) (Proteome Discoverer 1.2 beta, Thermo Fisher Scientific). Carboxyamidomethylation of cysteine was chosen as a fixed modification, and oxidation of methionine was chosen as a variable modification. The mass tolerance was set at 0.5 amu for the precursor ions and at 0.5 amu for fragment ions. Two missed cleavages were allowed. Scaffold (version 3, Proteome Software Inc.) was used to calculate the spectral counts and to validate MS/MS-based peptide and protein identifications as before. According to the default values in the Scaffold software, the following peptide thresholds were applied: SEQUEST: ÎCn &gt; 0.10 and XCorr &gt; 2.5 (2+), 3.5 (3+), and 3.5 (4+). Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm (<xref ref-type="bibr" rid="B9">9</xref>). Protein identifications were accepted if they could be established at greater than 99.0% probability (<xref ref-type="bibr" rid="B10">10</xref>) with at least two independent peptides.</p></sec><sec><title>Western Blotting</title><p>Aliquots of the NaCl, guanidine, and SDS extracts were mixed with denaturing sample buffer and boiled. 20 Î¼g of protein per sample were loaded and separated on 4â12% gradient gels as above. Proteins were then transferred on nitrocellulose membranes. Membranes were blocked in 5% fat-free milk powder in PBS and then probed for 16 h at 4 Â°C with primary antibodies to Î²-actin (sc-130656), periostin (sc-67233), and fibronectin (sc-56391). The antibodies were purchased from Santa Cruz Biotechnology and were used at a 1:500 dilution in 5% BSA. The membranes were then treated with the appropriate secondary, peroxidase-conjugated antibodies (Dako) at a 1:2000 dilution. Finally, the blots were imaged using enhanced chemiluminescence (ECL; GE Healthcare), and films were developed on a Xograph processor. The densitometry for the lanes from developed blots for periostin and asporin was performed using ImageJ software.</p></sec><sec><title>Gelatinolytic Zymography</title><p>Gelatinolytic zymograms were used to detect the presence of MMP-2 and -9 in the 0.5 <sc>m</sc> NaCl extracts. Extract aliquots (20 Î¼g of protein) were mixed with non-reducing sample buffer containing 100 m<sc>m</sc> Tris, pH 6.8, 40% glycerol, 0.2% SDS, and 0.02% bromphenol blue and separated by 10% SDS-PAGE in gels containing 0.5 mg/ml gelatin (Sigma-Aldrich). Prestained protein standards were run alongside the samples as before. To allow in-gel MMP activity, SDS was removed from the gels with three washes in a buffer containing 2% Triton X-100, 50 m<sc>m</sc> Tris, pH 7.4, and 200 m<sc>m</sc> NaCl for 45 min. Gels were then incubated for 16 h to detect MMP-9 or 36 h to detect MMP-2 at 37 Â°C in a buffer containing 50 m<sc>m</sc> Tris, pH 7.4, 200 m<sc>m</sc> NaCl, and 10 m<sc>m</sc> CaCl<sub>2</sub>. Finally, gels were stained for 60 min with Coomassie Brilliant Blue (Sigma-Aldrich) and destained for 2 h to visualize the MMPs.</p></sec><sec><title>Histochemistry</title><p>Small representative pieces from each aortic sample were placed in optimal cutting temperature (OCT) compound (BDH), which was subsequently frozen. The frozen tissue blocks were used to generate consecutive 7-Î¼m-thick cross-sections. The sections were air-dried (30 min) and fixed in 100% acetone for 20 min. Subsequently, sections were used either to generate hematoxylin- and eosin-stained histological slides or for immunohistochemical analysis using antibodies to podocan used at 2 Î¼g/ml (MAB4220) (R&amp;D Systems), sclerostin (sc-130258) used at 1 Î¼g/ml, and agrin (sc-25528) used at used at 2 Î¼g/ml (Santa Cruz Biotechnology). Negative controls were generated with either mouse (podocan) or rabbit (sclerostin and agrin) isotype IgG antibodies (Sigma-Aldrich) used at 2 Î¼g/ml. The immunostaining was generated using the DAB+ (diaminobenzidine) peroxidase-based chromogen system (Dako) according to the manufacturer's instructions. Images were taken by a Zeiss Axioplan 2ie microscope interfaced to AxioVision software (version 3.0.6).</p></sec><sec><title>Statistical Analysis of NaCl and Guanidine Extracts</title><p>For each clinical sample (<italic>n</italic> = 4) and biochemical fraction (<italic>n</italic> = 2) analyzed, we obtained a technical replicate by using the RePlay device. The reproducibility of the RePlay analysis was assessed by calculating the Pearson correlation coefficient for the spectral counts. All spectra from proteins identified with at least two unique peptides were included in the analysis, and no outliers were removed. The <italic>p</italic> value for the linear dependence between the RePlay runs was obtained using the Fisher transformation. To assess biological variability among the four clinical specimens, we computed the coefficient of variation for all identified proteins using Scaffold software (version 2.0.5, Proteome Software Inc.). A coefficient of variation exceeding 100% was applied as a cutoff. Statistical significance was determined by using analysis of variance (ANOVA). A <italic>p</italic> value &lt;0.05 was considered significant.</p></sec></sec></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title/><sec><title/><sec><title>Biochemical Extraction of Proteins in Extracellular Environment</title><p>Our extraction methodology was developed on human aortic samples obtained during cardiac surgery for aortic valve replacement of degenerative aortic valve stenosis. <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic> is a schematic summary of the methodology used in this study. The samples (<italic>n</italic> = 3) were macroscopically classified as normal during surgery, and upon histological examination, they showed no pathological signs. Extraction of the proteins of the vascular extracellular environment and reduction of the contamination with cellular proteins were achieved by a three-step extraction procedure. First, the tissue samples were treated with 0.5 <sc>m</sc> NaCl. The salt ions induce displacement of polyionic interactions between proteins, thus enabling the extraction of loosely bound extracellular proteins, including newly synthesized ECM proteins and degradation products (<xref ref-type="bibr" rid="B12">12</xref>), providing an overview of tissue turnover. The tissue was then decellularized using SDS. In contrast to other decellularization reagents, such as non-ionic detergents (Triton X-100) (<xref ref-type="bibr" rid="B13">13</xref>), 0.1% SDS has been previously shown to be very effective in solubilizing cytoplasmic and nuclear membranes, thereby removing cellular components from tissues (<xref ref-type="bibr" rid="B14">14</xref>). However, the ionic detergent above its critical micelle concentration can also cause protein denaturation and disrupt native ECM proteins (<xref ref-type="bibr" rid="B15">15</xref>).</p><fig id="F1" position="float"><label>Fig. 1.</label><caption><p><bold>Identification of extracellular proteins in human aortas.</bold> <italic>A</italic>, schematic summary. Biochemical subfractionation was used for the enrichment of extracellular space proteins before proteomic analysis. <italic>B</italic>, validation of decellularization by hematoxylin/eosin staining. Representative images of a hematoxylin/eosin-stained human aorta before (<italic>left panel</italic>) and after decellularization with 0.08% SDS (<italic>right panel</italic>) are shown. <italic>L</italic>, lumen; <italic>I</italic>, intima; <italic>M</italic>, media. <italic>Arrows</italic> depict the intima/media border. Note the loss of nuclear (<italic>blue</italic>; hematoxylin) and cytoplasmic contents (<italic>pink</italic>; eosin), whereas other eosinophilic structures, such as collagen fibers, are preserved. <italic>C</italic>, immunoblotting and silver staining. The ECM glycoprotein AEBP1 is found in the NaCl and guanidine (<italic>Guan</italic>) extracts, which are enriched in proteins of the extracellular space (<italic>upper panel</italic>). Cytoplasmic Î²-actin is predominantly found in the SDS extracts (<italic>middle panel</italic>), demonstrating successful depletion of cellular contents. Silver staining of proteins from all extracts separated by one-dimensional SDS-PAGE shows the pattern of proteins extracted in the three different extraction steps (<italic>bottom panel</italic>).</p></caption><graphic xlink:href="zjw0091036770001"/></fig><p>To substantially remove the cellular material while preserving the ECM and its associated proteins as much as possible, we used 2.8 m<sc>m</sc> (0.08%) SDS in distilled water. This concentration is well below the critical micelle concentration of SDS in distilled water, which is 8 m<sc>m</sc> (<xref ref-type="bibr" rid="B16">16</xref>). In addition, at this concentration, SDS is effective in solubilizing cell membrane lipid bilayers (<xref ref-type="bibr" rid="B17">17</xref>). Treatment with 0.08% SDS was sufficient to remove most cellular components as shown by the marked reduction of nuclear staining (hematoxylin; <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>, <italic>blue</italic>). The cytoplasmic staining (eosin; <italic>pink</italic>) was also reduced, but other eosinophilic structures, such as collagen and elastin, were preserved in the tissue. Finally, the specimens were subjected to denaturing extraction in a 4 <sc>m</sc> guanidine HCl buffer. Guanidine HCl extractions were developed more than 40 years ago as a very effective way to solubilize most of the strongly bound ECM components, including large aggregating proteoglycans (versican, aggrecan, etc.), small proteoglycans (decorin, biglycan, etc.), cell attachment matrix glycoproteins (such as type VI collagen, fibronectins, and laminins), and basement membrane components (perlecan, type IV collagen, etc.). Guanidine induces disaggregation of ECM components by destabilizing the ionic, disulfide-dependent protein conformations (<xref ref-type="bibr" rid="B18">18</xref>). Following dissociative extraction, only the insoluble, heavily cross-linked interstitial matrix, namely type I and III collagens and elastin, remains in the tissue. Western blotting confirmed that Î²-actin immunoreactivity is predominantly found in the SDS extracts (<xref ref-type="fig" rid="F1">Fig 1</xref><italic>C</italic>, <italic>middle panel</italic>), which also had the highest protein concentration per milliliter (<ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 1</ext-link>). On the other hand, the extracellular AEBP1 isoform, an ECM-associated glycoprotein, was detected in the NaCl and guanidine extracts by Western blotting (<xref ref-type="fig" rid="F1">Fig 1</xref><italic>C</italic>, <italic>upper panel</italic>), indicating that these extracts are enriched in proteins of the extracellular space. Silver staining revealed a distinct but reproducible protein pattern in the three different extraction steps (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>, <italic>bottom panel</italic>).</p><p>The different extracts were subjected to enzymatic deglycosylation to remove chondroitin, keratan, and heparan sulfate glycosaminoglycan (GAG) chains from the matrix glycoproteins. Deglycosylation is a critical step in our methodology. First, GAGs increase the molecular weight of glycoproteins and affect their separation and resolution by one-dimensional electrophoresis. Second, the presence of GAGs greatly reduces the chance for the identification of proteoglycans by mass spectrometry.</p></sec><sec><title>Proteomics Analysis of Extracts</title><p>After separation by SDS-PAGE, protein bands were excised from silver-stained gels, subjected to in-gel tryptic digestion, and analyzed by LC-MS/MS. The peptides were injected into a high mass accuracy ion trap (LTQ-Orbitrap XL, Thermo Fisher Scientific) using RePlay (Advion). This injection system splits the gradient from the analytical column and allows the reanalysis of the same sample in a single LC-MS/MS run (<xref ref-type="bibr" rid="B8">8</xref>). 272 and 321 proteins were identified in the NaCl and guanidine extracts, respectively. All the peptides identified by LC-MS/MS in the NaCl and guanidine extracts are shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Tables 1 and 2</ext-link>. According to their gene ontology annotation (European Molecular Biology Laboratory-European Bioinformatics Institute database, <ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org">www.uniprot.org</ext-link>), a quarter of these proteins were located in the extracellular space: among the 61 extracellular proteins in the NaCl extracts (<xref ref-type="table" rid="TI">Table I</xref>) and the 84 extracellular proteins in the guanidine extracts (<xref ref-type="table" rid="TII">Table II</xref>), proteins highlighted with Footnote b were, to the best of our knowledge, identified for the first time in the vasculature by proteomics. Lipoproteins were included (even though they are plasma-derived) because of their intimate relationship with proteoglycans and their relevance in cardiovascular pathology. The classification of the identified extracellular space proteins in the NaCl and the guanidine extracts is shown in <xref ref-type="fig" rid="F2">Fig. 2</xref>, <italic>A</italic> and <italic>B</italic>. As expected, the denaturing guanidine extracts were particularly enriched in ECM proteoglycans and glycoproteins (50%), whereas the mildly dissociative NaCl extracts were enriched in proteases and protease inhibitors (21%), indicating the importance of this subproteome for studying proteolytic processes in tissues.</p><table-wrap id="TI" position="float"><label>Table I</label><caption><title>Extracellular space proteins identified by proteomics in three NaCl extracts</title><p>COMP, cartilage oligomeric matrix protein; IGF, insulin-like growth factor.</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="center" rowspan="1" colspan="1">Protein name</th><th align="center" rowspan="1" colspan="1">Swiss-Prot accession name</th><th align="center" rowspan="1" colspan="1">Molecular mass</th><th align="center" rowspan="1" colspan="1">Unique peptides, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Unique spectra, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Coverage</th><th align="center" rowspan="1" colspan="1">Total spectra,<xref ref-type="table-fn" rid="TFI-1"><sup><italic>a</italic></sup></xref><italic>n</italic></th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>kDa</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Proteoglycans and glycoproteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââLumican</td><td align="left" rowspan="1" colspan="1">LUM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">20.0</td><td align="char" char="." rowspan="1" colspan="1">249</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTenascin-X</td><td align="left" rowspan="1" colspan="1">TENX_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">464</td><td align="char" char="." rowspan="1" colspan="1">66</td><td align="char" char="." rowspan="1" colspan="1">66</td><td align="char" char="." rowspan="1" colspan="1">8.1</td><td align="char" char="." rowspan="1" colspan="1">156</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-3</td><td align="left" rowspan="1" colspan="1">FBLN3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">22.0</td><td align="char" char="." rowspan="1" colspan="1">155</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAdipocyte enhancer-binding protein 1<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">AEBP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">131</td><td align="char" char="." rowspan="1" colspan="1">37</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">11.0</td><td align="char" char="." rowspan="1" colspan="1">153</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibronectin</td><td align="left" rowspan="1" colspan="1">FINC_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">263</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">7.3</td><td align="char" char="." rowspan="1" colspan="1">111</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPerlecan</td><td align="left" rowspan="1" colspan="1">PGBM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">469</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">2.5</td><td align="char" char="." rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMimecan</td><td align="left" rowspan="1" colspan="1">MIME_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">49</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââVersican</td><td align="left" rowspan="1" colspan="1">CSPG2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">373</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="char" char="." rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTetranectin</td><td align="left" rowspan="1" colspan="1">TETN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="char" char="." rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibromodulin</td><td align="left" rowspan="1" colspan="1">FMOD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7.4</td><td align="char" char="." rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-1</td><td align="left" rowspan="1" colspan="1">FBLN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">25</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLatent TGFÎ²-binding protein 2<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LTBP2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">195</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">5.2</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââThrombospondin-1</td><td align="left" rowspan="1" colspan="1">TSP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">5.1</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPodocan<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">PODN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">69</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">6.9</td><td align="char" char="." rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibrillin-1</td><td align="left" rowspan="1" colspan="1">FBN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">312</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="char" char="." rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-5</td><td align="left" rowspan="1" colspan="1">FBLN5_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7.8</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-1</td><td align="left" rowspan="1" colspan="1">LEG1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">26.0</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââDecorin</td><td align="left" rowspan="1" colspan="1">PGS2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">10.0</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLatent TGFÎ²-binding protein 4<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LTBP4_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">173</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1.6</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââClusterin</td><td align="left" rowspan="1" colspan="1">CLUS_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3.6</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCOMP</td><td align="left" rowspan="1" colspan="1">COMP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">6.3</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTenascin</td><td align="left" rowspan="1" colspan="1">TENA_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">241</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0.95</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââDermatopontin</td><td align="left" rowspan="1" colspan="1">DERM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">9.5</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Other ECM-associated proteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââExtracellular superoxide dismutase</td><td align="left" rowspan="1" colspan="1">SODE_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">46.0</td><td align="char" char="." rowspan="1" colspan="1">209</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPigment epithelium-derived factor</td><td align="left" rowspan="1" colspan="1">PEDF_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">46</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">16.0</td><td align="char" char="." rowspan="1" colspan="1">82</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSerum amyloid P-component</td><td align="left" rowspan="1" colspan="1">SAMP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">26.0</td><td align="char" char="." rowspan="1" colspan="1">62</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââIGF-binding protein 7<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">IBP7_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">21.0</td><td align="char" char="." rowspan="1" colspan="1">47</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein A-I</td><td align="left" rowspan="1" colspan="1">APOA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">25.0</td><td align="char" char="." rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein A-IV</td><td align="left" rowspan="1" colspan="1">APOA4_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">17.0</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein H<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">APOH_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââHepatoma-derived growth factor<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">HDGF_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7.9</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSecreted frizzled-related protein 1<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SFRP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">9.2</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCeruloplasmin</td><td align="left" rowspan="1" colspan="1">CERU_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">122</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSecreted frizzled-related protein 3<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SFRP3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">9.2</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein D</td><td align="left" rowspan="1" colspan="1">APOD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">20.0</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein E</td><td align="left" rowspan="1" colspan="1">APOE_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7.6</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLIM and cysteine-rich domains protein 1<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LMCD1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7.7</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSpondin-1<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SPON1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">91</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2.7</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTarget of Nesh-SH3<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TARSH_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">119</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2.6</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteases and protease inhibitors</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââTryptase Î²-1<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TRYB1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">22.0</td><td align="char" char="." rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProcollagen C-endopeptidase enhancer 1</td><td align="left" rowspan="1" colspan="1">PCOC1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">7.8</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCathepsin G<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CATG_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">6.7</td><td align="char" char="." rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCalreticulin</td><td align="left" rowspan="1" colspan="1">CALR_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">11.0</td><td align="char" char="." rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCathepsin Z<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CATZ_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7.3</td><td align="char" char="." rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPlasma glutamate carboxypeptidase<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">PGCP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">4.2</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCathepsin D</td><td align="left" rowspan="1" colspan="1">CATD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">7.0</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLeukocyte elastase inhibitor</td><td align="left" rowspan="1" colspan="1">ILEU_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">9.0</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProactivator polypeptide<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SAP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">58</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5.3</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMMP-2<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">MMP2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">74</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââKallistatin<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">KAIN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">49</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">4.7</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCarboxypeptidase-like protein X2<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CPXM2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>kDa</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Collagens</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XIV)<xref ref-type="table-fn" rid="TFI-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">COEA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">233</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XII)</td><td align="left" rowspan="1" colspan="1">COCA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">333</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">2.8</td><td align="char" char="." rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-3(VI)</td><td align="left" rowspan="1" colspan="1">CO6A3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">344</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="char" char="." rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XVIII)</td><td align="left" rowspan="1" colspan="1">COIA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">178</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="char" char="." rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(VI)</td><td align="left" rowspan="1" colspan="1">CO6A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">109</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3.0</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XV)</td><td align="left" rowspan="1" colspan="1">COFA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">142</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(I)</td><td align="left" rowspan="1" colspan="1">CO1A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr></tbody></table><table-wrap-foot><fn id="TFI-1"><p><sup><italic>a</italic></sup> Sum of all spectra identified for each protein in the three biological samples, performed with two technical replicates each.</p></fn><fn id="TFI-2"><p><sup><italic>b</italic></sup> Proteins found for the first time by proteomics in the vasculature.</p></fn></table-wrap-foot></table-wrap><table-wrap id="TII" position="float"><label>Table II</label><caption><title>Extracellular space proteins identified by proteomics in three guanidine extracts</title><p>IGF, insulin-like growth factor.</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="center" rowspan="1" colspan="1">Protein name</th><th align="center" rowspan="1" colspan="1">Swiss-Prot accession name</th><th align="center" rowspan="1" colspan="1">Molecular mass</th><th align="center" rowspan="1" colspan="1">Unique peptides, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Unique spectra, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Coverage</th><th align="center" rowspan="1" colspan="1">Total spectra,<xref ref-type="table-fn" rid="TFII-1"><sup><italic>a</italic></sup></xref><italic>n</italic></th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>kDa</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Proteoglycans and glycoproteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââPerlecan</td><td align="left" rowspan="1" colspan="1">PGBM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">469</td><td align="char" char="." rowspan="1" colspan="1">367</td><td align="char" char="." rowspan="1" colspan="1">481</td><td align="char" char="." rowspan="1" colspan="1">19.0</td><td align="char" char="." rowspan="1" colspan="1">1596</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibronectin</td><td align="left" rowspan="1" colspan="1">FINC_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">263</td><td align="char" char="." rowspan="1" colspan="1">182</td><td align="char" char="." rowspan="1" colspan="1">218</td><td align="char" char="." rowspan="1" colspan="1">20.0</td><td align="char" char="." rowspan="1" colspan="1">1028</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââVersican</td><td align="left" rowspan="1" colspan="1">CSPG2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">373</td><td align="char" char="." rowspan="1" colspan="1">76</td><td align="char" char="." rowspan="1" colspan="1">89</td><td align="char" char="." rowspan="1" colspan="1">4.4</td><td align="char" char="." rowspan="1" colspan="1">681</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAggrecan</td><td align="left" rowspan="1" colspan="1">PGCA_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">250</td><td align="char" char="." rowspan="1" colspan="1">70</td><td align="char" char="." rowspan="1" colspan="1">82</td><td align="char" char="." rowspan="1" colspan="1">6.3</td><td align="char" char="." rowspan="1" colspan="1">451</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââBiglycan</td><td align="left" rowspan="1" colspan="1">PGS1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">56</td><td align="char" char="." rowspan="1" colspan="1">62</td><td align="char" char="." rowspan="1" colspan="1">36.0</td><td align="char" char="." rowspan="1" colspan="1">352</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLactadherin</td><td align="left" rowspan="1" colspan="1">MFGM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="char" char="." rowspan="1" colspan="1">67</td><td align="char" char="." rowspan="1" colspan="1">48.0</td><td align="char" char="." rowspan="1" colspan="1">309</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProlargin</td><td align="left" rowspan="1" colspan="1">PRELP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">78</td><td align="char" char="." rowspan="1" colspan="1">37.0</td><td align="char" char="." rowspan="1" colspan="1">283</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPeriostin</td><td align="left" rowspan="1" colspan="1">POSTN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">117</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="char" char="." rowspan="1" colspan="1">257</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLumican</td><td align="left" rowspan="1" colspan="1">LUM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">58</td><td align="char" char="." rowspan="1" colspan="1">30.0</td><td align="char" char="." rowspan="1" colspan="1">204</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââDecorin</td><td align="left" rowspan="1" colspan="1">PGS2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">51</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="char" char="." rowspan="1" colspan="1">173</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââClusterin</td><td align="left" rowspan="1" colspan="1">CLUS_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">23.0</td><td align="char" char="." rowspan="1" colspan="1">173</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTenascin-X</td><td align="left" rowspan="1" colspan="1">TENX_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">464</td><td align="char" char="." rowspan="1" colspan="1">79</td><td align="char" char="." rowspan="1" colspan="1">79</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">140</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLaminin subunit Î³-1</td><td align="left" rowspan="1" colspan="1">LAMC1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">178</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">18.0</td><td align="char" char="." rowspan="1" colspan="1">129</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLink protein 1</td><td align="left" rowspan="1" colspan="1">HPLN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">33.0</td><td align="char" char="." rowspan="1" colspan="1">117</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLaminin subunit Î²-2</td><td align="left" rowspan="1" colspan="1">LAMB2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">196</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">104</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââVitronectin</td><td align="left" rowspan="1" colspan="1">VTNC_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">54</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">102</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââNidogen-1</td><td align="left" rowspan="1" colspan="1">NID1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">136</td><td align="char" char="." rowspan="1" colspan="1">56</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">101</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAdipocyte enhancer-binding protein 1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">AEBP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">131</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">7.6</td><td align="char" char="." rowspan="1" colspan="1">94</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLaminin subunit Î±-5</td><td align="left" rowspan="1" colspan="1">LAMA5_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">400</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="char" char="." rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTenascin</td><td align="left" rowspan="1" colspan="1">TENA_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">241</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">5.6</td><td align="char" char="." rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMimecan</td><td align="left" rowspan="1" colspan="1">MIME_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââEGF-containing fibulin-like ECM protein 1</td><td align="left" rowspan="1" colspan="1">FBLN3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-5</td><td align="left" rowspan="1" colspan="1">FBLN5_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-1</td><td align="left" rowspan="1" colspan="1">LEG1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">53.0</td><td align="char" char="." rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTGFÎ²-induced protein ig-h3</td><td align="left" rowspan="1" colspan="1">BGH3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">75</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">35</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââEMILIN-1</td><td align="left" rowspan="1" colspan="1">EMIL1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">3.0</td><td align="char" char="." rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-1</td><td align="left" rowspan="1" colspan="1">FBLN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLatent TGFÎ²-binding protein 2<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LTBP2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">195</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">2.7</td><td align="char" char="." rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibromodulin</td><td align="left" rowspan="1" colspan="1">FMOD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">8.2</td><td align="char" char="." rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMicrofibril-associated glycoprotein 4</td><td align="left" rowspan="1" colspan="1">MFAP4_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââDermatopontin</td><td align="left" rowspan="1" colspan="1">DERM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibrillin-1</td><td align="left" rowspan="1" colspan="1">FBN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">312</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">2.4</td><td align="char" char="." rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLatent TGFÎ²-binding protein 4<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LTBP4_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">173</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">4.2</td><td align="char" char="." rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââNidogen-2</td><td align="left" rowspan="1" colspan="1">NID2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">151</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">3.5</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAgrin<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">AGRIN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">215</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAsporin</td><td align="left" rowspan="1" colspan="1">ASPN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">11.0</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCartilage oligomeric matrix protein</td><td align="left" rowspan="1" colspan="1">COMP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3.6</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââThrombospondin-1</td><td align="left" rowspan="1" colspan="1">TSP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1.8</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMatrix Gla protein</td><td align="left" rowspan="1" colspan="1">MGP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">13.0</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-3</td><td align="left" rowspan="1" colspan="1">LEG3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">6.0</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSclerostin<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SOST_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">5.6</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMatrilin-2<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">MATN2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Other ECM-associated proteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââSerum amyloid P-component</td><td align="left" rowspan="1" colspan="1">SAMP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">33.0</td><td align="char" char="." rowspan="1" colspan="1">169</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTubulointerstitial nephritis antigen-like<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TINAL_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">46</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">21.0</td><td align="char" char="." rowspan="1" colspan="1">131</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââExtracellular superoxide dismutase</td><td align="left" rowspan="1" colspan="1">SODE_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">25.0</td><td align="char" char="." rowspan="1" colspan="1">102</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTarget of Nesh-SH3<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TARSH_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">119</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">8.6</td><td align="char" char="." rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââIGF-binding protein 7<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">IBP7_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">28.0</td><td align="char" char="." rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCysteine-rich protein 2</td><td align="left" rowspan="1" colspan="1">CRIP2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">25.0</td><td align="char" char="." rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTGFÎ²-1-induced transcript 1 protein<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TGFI1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLIM and cysteine-rich domains protein 1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LMCD1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">34.0</td><td align="char" char="." rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein H<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">APOH_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">9.0</td><td align="char" char="." rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-3-binding protein</td><td align="left" rowspan="1" colspan="1">LG3BP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12.0</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââRPE-spondin<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">RPESP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">22.0</td><td align="char" char="." rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>kDa</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââCarboxypeptidase-like protein X2<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CPXM2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">7.3</td><td align="char" char="." rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLatent TGFÎ²-binding protein, isoform 1S<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LTB1S_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">153</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">2.7</td><td align="char" char="." rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPigment epithelium derived factor</td><td align="left" rowspan="1" colspan="1">PEDF_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">46</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">8.6</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSecreted frizzled-related protein 1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SFRP1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">8.9</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProperdin<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">PROP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">51</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">5.1</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââSpondin-1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SPON1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">91</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3.0</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââNeutrophil defensin 1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">DEF1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">9.6</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteases and protease inhibitors</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââSerine protease HTRA1</td><td align="left" rowspan="1" colspan="1">HTRA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">51</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">13.0</td><td align="char" char="." rowspan="1" colspan="1">68</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââChymase<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CMA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">11.0</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLysyl oxidase homolog 1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">LOXL1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">63</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">7.3</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMetalloproteinase inhibitor 3</td><td align="left" rowspan="1" colspan="1">TIMP3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">17.0</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTryptase Î²-1<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">TRYB1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">9.8</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProcollagen C-endopeptidase enhancer 1</td><td align="left" rowspan="1" colspan="1">PCOC1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">6.7</td><td align="char" char="." rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCathepsin G<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">CATG_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCathepsin D</td><td align="left" rowspan="1" colspan="1">CATD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2.7</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââAntileukoproteinase<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">SLPI_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMyeloblastin<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">PRTN3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">4.7</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Collagens</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-3(VI)</td><td align="left" rowspan="1" colspan="1">CO6A3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">344</td><td align="char" char="." rowspan="1" colspan="1">164</td><td align="char" char="." rowspan="1" colspan="1">186</td><td align="char" char="." rowspan="1" colspan="1">20.0</td><td align="char" char="." rowspan="1" colspan="1">898</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XIV)<xref ref-type="table-fn" rid="TFII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">COEA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="char" char="." rowspan="1" colspan="1">136</td><td align="char" char="." rowspan="1" colspan="1">150</td><td align="char" char="." rowspan="1" colspan="1">20.0</td><td align="char" char="." rowspan="1" colspan="1">529</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XVIII)</td><td align="left" rowspan="1" colspan="1">COIA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">178</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">5.9</td><td align="char" char="." rowspan="1" colspan="1">374</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(VI)</td><td align="left" rowspan="1" colspan="1">CO6A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">109</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">71</td><td align="char" char="." rowspan="1" colspan="1">16.0</td><td align="char" char="." rowspan="1" colspan="1">282</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(VI)</td><td align="left" rowspan="1" colspan="1">CO6A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">109</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">19.0</td><td align="char" char="." rowspan="1" colspan="1">155</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(IV)</td><td align="left" rowspan="1" colspan="1">CO4A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">168</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">3.9</td><td align="char" char="." rowspan="1" colspan="1">139</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XV)</td><td align="left" rowspan="1" colspan="1">COFA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">142</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">7.5</td><td align="char" char="." rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XII)</td><td align="left" rowspan="1" colspan="1">COCA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">333</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">4.0</td><td align="char" char="." rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(I)</td><td align="left" rowspan="1" colspan="1">CO1A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">3.5</td><td align="char" char="." rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(I)</td><td align="left" rowspan="1" colspan="1">CO1A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">139</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">5.9</td><td align="char" char="." rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(VIII)</td><td align="left" rowspan="1" colspan="1">CO8A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1.3</td><td align="char" char="." rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(V)</td><td align="left" rowspan="1" colspan="1">CO5A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">184</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(VIII)</td><td align="left" rowspan="1" colspan="1">CO8A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">67</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(IV)</td><td align="left" rowspan="1" colspan="1">CO4A1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">161</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1.8</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr></tbody></table><table-wrap-foot><fn id="TFII-1"><p><sup><italic>a</italic></sup> Sum of all spectra identified for each protein in the three biological samples, performed with two technical replicates each.</p></fn><fn id="TFII-2"><p><sup><italic>b</italic></sup> Proteins found for the first time by proteomics in the vasculature.</p></fn></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Fig. 2.</label><caption><p><bold>Protein categories.</bold> The classification and numerical distribution of the identified extracellular proteins in the NaCl (<italic>A</italic>), guanidine (<italic>B</italic>), and SDS (<italic>C</italic>) extracts are shown. The <italic>size</italic> of the <italic>doughnut charts</italic> is representative of the number of extracellular space proteins identified in the different extracts.</p></caption><graphic xlink:href="zjw0091036770002"/></fig><p>To identify proteins of the extracellular space extracted by 0.08% SDS, we performed proteomics analysis of the SDS extracts. Because of the increased complexity of these samples, tryptic peptides were injected into a dual pressure, linear ion trap (LTQ Velos, Thermo Fisher Scientific) with faster scan speed. As expected, the majority of the identified proteins were cellular (data not shown), and only 28 extracellular space proteins were identified (<xref ref-type="table" rid="TIII">Table III</xref>). The classification of the identified extracellular space proteins in the SDS extracts is shown in <xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>. Interestingly, apart from type XIV collagen, all other extracellular space proteins have been previously identified by proteomics in the vasculature. Also, of note is the absence of proteases and protease inhibitors in these extracts either because they are obscured by abundant cellular proteins or because those that remain in the tissue following 0.5 <sc>m</sc> NaCl extraction are tightly bound to the ECM and require dissociative conditions to be extracted (<italic>i.e.</italic> guanidine). Peptides of extracellular space proteins identified by LC-MS/MS in the SDS extracts are shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Table 3</ext-link>.</p><table-wrap id="TIII" position="float"><label>Table III</label><caption><title>Extracellular space proteins identified by proteomics in three SDS extracts</title></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="center" rowspan="1" colspan="1">Protein name</th><th align="center" rowspan="1" colspan="1">Swiss-Prot accession name</th><th align="center" rowspan="1" colspan="1">Molecular mass</th><th align="center" rowspan="1" colspan="1">Unique peptides, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Unique spectra, <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Coverage</th><th align="center" rowspan="1" colspan="1">Total spectra,<xref ref-type="table-fn" rid="TFIII-1"><sup><italic>a</italic></sup></xref><italic>n</italic></th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>kDa</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Proteoglycans and glycoproteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââBiglycan</td><td align="left" rowspan="1" colspan="1">PGS1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">32.6</td><td align="char" char="." rowspan="1" colspan="1">141</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââDecorin</td><td align="left" rowspan="1" colspan="1">PGS2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">33.1</td><td align="char" char="." rowspan="1" colspan="1">85</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââMimecan</td><td align="left" rowspan="1" colspan="1">MIME_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">76</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLumican</td><td align="left" rowspan="1" colspan="1">LUM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="char" char="." rowspan="1" colspan="1">24.6</td><td align="char" char="." rowspan="1" colspan="1">72</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââProlargin</td><td align="left" rowspan="1" colspan="1">PRELP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">22.5</td><td align="char" char="." rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibronectin</td><td align="left" rowspan="1" colspan="1">FINC_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">263</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">8.1</td><td align="char" char="." rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââVersican</td><td align="left" rowspan="1" colspan="1">CSPG2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">373</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">2.3</td><td align="char" char="." rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLactadherin</td><td align="left" rowspan="1" colspan="1">MFGM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">21.2</td><td align="char" char="." rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPerlecan</td><td align="left" rowspan="1" colspan="1">PGBM_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">469</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">2.9</td><td align="char" char="." rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââClusterin</td><td align="left" rowspan="1" colspan="1">CLUS_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">14.2</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââEGF-containing fibulin-like ECM protein 1</td><td align="left" rowspan="1" colspan="1">FBLN3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">10.6</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââPeriostin</td><td align="left" rowspan="1" colspan="1">POSTN_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">4.8</td><td align="char" char="." rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-1</td><td align="left" rowspan="1" colspan="1">LEG1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">23.0</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââTenascin</td><td align="left" rowspan="1" colspan="1">TENA_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">241</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââVitronectin</td><td align="left" rowspan="1" colspan="1">VTNC_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">54</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">5.6</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLink protein 1</td><td align="left" rowspan="1" colspan="1">HPLN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">13.0</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-1</td><td align="left" rowspan="1" colspan="1">FBLN1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3.8</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââLaminin subunit Î±-4</td><td align="left" rowspan="1" colspan="1">LAMA4_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">203</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1.9</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââFibulin-5</td><td align="left" rowspan="1" colspan="1">FBLN5_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">6.0</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Other ECM-associated proteins</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein E</td><td align="left" rowspan="1" colspan="1">APOE_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">17.7</td><td align="char" char="." rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââExtracellular superoxide dismutase</td><td align="left" rowspan="1" colspan="1">SODE_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">26</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">24.0</td><td align="char" char="." rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein B</td><td align="left" rowspan="1" colspan="1">APOD_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="char" char="." rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââApolipoprotein A-I</td><td align="left" rowspan="1" colspan="1">APOA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââGalectin-3-binding protein</td><td align="left" rowspan="1" colspan="1">LG3BP_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">6.7</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Collagens</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-3(VI)</td><td align="left" rowspan="1" colspan="1">CO6A3_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">344</td><td align="char" char="." rowspan="1" colspan="1">57</td><td align="char" char="." rowspan="1" colspan="1">58</td><td align="char" char="." rowspan="1" colspan="1">7.4</td><td align="char" char="." rowspan="1" colspan="1">109</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-2(VI)</td><td align="left" rowspan="1" colspan="1">CO6A2_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">109</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">2.4</td><td align="char" char="." rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XIV)<xref ref-type="table-fn" rid="TFIII-2"><sup><italic>b</italic></sup></xref></td><td align="left" rowspan="1" colspan="1">COEA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">3.6</td><td align="char" char="." rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">ââââCollagen Î±-1(XVIII)</td><td align="left" rowspan="1" colspan="1">COIA1_HUMAN</td><td align="char" char="." rowspan="1" colspan="1">178</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr></tbody></table><table-wrap-foot><fn id="TFIII-1"><p><sup><italic>a</italic></sup> Sum of all spectra identified for each protein in the three biological samples, performed with two technical replicates each.</p></fn><fn id="TFIII-2"><p><sup><italic>b</italic></sup> Proteins found for the first time by proteomics in the vasculature.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Identification of Podocan, Sclerostin, and Agrin</title><p>Among the identified proteins in the NaCl and guanidine extracts were three recently discovered glycoproteins that have never been detected in the aortic ECM at the protein level. Podocan, an atypical proteoglycan, which has so far been found in the basement membrane of the glomeruli as a product of kidney podocytes (<xref ref-type="bibr" rid="B19">19</xref>), was detected in the NaCl extracts. Immunohistological staining confirmed the presence of podocan in the aortic intima (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>A</italic>; the isotype negative control is shown in <xref ref-type="fig" rid="F3">Fig. 3</xref><italic>B</italic>). Sclerostin, a potent bone morphogenetic protein antagonist secreted by osteoblasts and osteocytes (<xref ref-type="bibr" rid="B20">20</xref>), was identified in the guanidine extract and was localized in the subendothelial layer of the aortic intima (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>C</italic>; the isotype negative control is shown in <xref ref-type="fig" rid="F3">Fig. 3</xref><italic>D</italic>). The function of these glycoproteins in the vasculature is to date unknown. Finally, agrin is a large heparan sulfate proteoglycan. It has been found in the basement membrane of various tissues and is known to participate in the organization of the neuromuscular junction (<xref ref-type="bibr" rid="B21">21</xref>). Immunohistochemical staining confirmed the presence of agrin on the aortic endothelium (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>E</italic>; the isotype negative control is shown in <xref ref-type="fig" rid="F3">Fig. 3</xref><italic>F</italic>), which is also the site for the accumulation of other heparan sulfate proteoglycans, such as perlecan (<xref ref-type="bibr" rid="B22">22</xref>). It is therefore possible that agrin participates in the formation of the vascular endothelial barrier. Representative MS/MS spectra for the three glycoproteins are shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 2</ext-link>.</p><fig id="F3" position="float"><label>Fig. 3.</label><caption><p><bold>Confirmation of podocan, sclerostin, and agrin in aortic ECM.</bold> Immunohistological staining confirmed the presence of podocan in the aortic intima (<italic>A</italic>). Immunoreactivity appears in <italic>brown</italic> (<italic>magnification</italic>, 20Ã; <italic>inset magnification</italic>, 60Ã). Nuclei are counterstained with Mayer's hematoxylin (<italic>blue</italic>). Sclerostin (<italic>C</italic>) was localized in the subendothelial layer of the aortic intima. Finally, immunohistochemical staining confirmed the presence of agrin (<italic>E</italic>). Agrin is localized on the aortic endothelium. The respective isotype negative controls are shown in <italic>B</italic>, <italic>D</italic>, and <italic>F</italic>, respectively. The specificity of the sclerostin and agrin antibodies was confirmed by immunoblotting (data not shown). The aortic specimens were from a 44-year old female (<italic>A</italic>, <italic>B</italic>) and a 55-year old male patient (<italic>CâF</italic>).</p></caption><graphic xlink:href="zjw0091036770003"/></fig></sec><sec><title>Evaluation of RePlay</title><p>For the wider application of proteomics in clinical research, it is essential to maximize the information obtained from valuable clinical samples. Given the scarcity of human tissue available, we used the RePlay device (Advion), which allowed us to obtain a technical replicate from each clinical specimen in a single LC-MS/MS run. Representative examples of chromatograms using RePlay are shown in <xref ref-type="fig" rid="F4">Fig. 4</xref>, <italic>A</italic> and <italic>B</italic>. Correlation analyses of the spectral counts in the three NaCl extracts and the three guanidine extracts are presented in <xref ref-type="fig" rid="F4">Fig. 4</xref>, <italic>C</italic> and <italic>D</italic>. The mean spectral counts for the NaCl and the guanidine extracts were 32.7 Â± 9.9 (median, 9.5) and 126.5 Â± 41 (median, 40), respectively. The <italic>R</italic><sup>2</sup> values (Pearson correlation coefficient) from all six extracts exceeded 0.94 (<italic>p</italic> values &lt;0.001), demonstrating good reproducibility in the duplicate analyses (<ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 3</ext-link>).</p><fig id="F4" position="float"><label>Fig. 4.</label><caption><p><bold>Evaluation of RePlay analysis.</bold> Representative chromatograms for a NaCl (<italic>A</italic>) and a guanidine extract (<italic>B</italic>) using RePlay are shown. The RePlay device allows the reanalysis of the same sample during a single LC-MS/MS run. The combined correlation of the spectral counts obtained by RePlay in the three NaCl extracts (<italic>C</italic>) and in the three guanidine extracts (<italic>D</italic>) demonstrates the good correlation between the technical replicates (Correlation for each of the six extrats can be found in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 3</ext-link>.). No RePlay analysis was performed for the SDS extracts.</p></caption><graphic xlink:href="zjw0091036770004"/></fig><p>Because of their scarcity, MMPs are rarely detected by tissue proteomics (<xref ref-type="bibr" rid="B23">23</xref>). Our subfractionation, however, enabled us to obtain spectral evidence for the presence of MMP-2 in one of the NaCl extracts (aortic sample 1). Consistent with our proteomics data, gelatin zymography confirmed the presence of MMP-2 in this sample (<xref ref-type="fig" rid="F5">Fig. 5</xref><italic>A</italic>). A representative MS/MS spectrum for MMP-2 is shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 4A</ext-link>. Importantly, the non-denaturing composition of the NaCl buffer allowed the detection of MMP-2 directly without further processing of the extracts.</p><fig id="F5" position="float"><label>Fig. 5.</label><caption><p><bold>Validation of proteomics data.</bold> Gelatin zymography confirmed the presence of MMP-2 in one of the three NaCl extracts (<italic>A</italic>). Periostin (<italic>B</italic>, <italic>upper panel</italic>) and asporin (<italic>B</italic>, <italic>bottom panel</italic>) were validated by immunoblotting in the guanidine extracts (on the same blotting membrane; first, asporin; and second, reprobing for periostin). The total protein loading control for the extracts can be seen in <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>, <italic>bottom panel</italic>. For periostin and asporin, the relative band intensity of the immunoblots was measured, and the values were correlated with the spectral counts of the original and the RePlay analysis (<italic>n</italic> = 2, mean Â± S.D. <italic>Error bars</italic> denote standard deviation.) (<italic>C</italic> and <italic>D</italic>).</p></caption><graphic xlink:href="zjw0091036770005"/></fig><p>In the guanidine extracts, we performed Western immunoblotting for the ECM protein periostin, which was unambiguously identified (<xref ref-type="fig" rid="F5">Fig. 5</xref><italic>B</italic>, <italic>upper panel</italic>). Periostin mRNA was recently shown to be expressed in rat carotid arteries following balloon injury (<xref ref-type="bibr" rid="B24">24</xref>). We also confirmed the presence of the scarce glycoprotein asporin in the vascular ECM (<xref ref-type="fig" rid="F5">Fig. 5</xref><italic>B</italic>, <italic>bottom panel</italic>). Its biological role is to date unclear, but it was recently shown to inhibit TGFÎ²-induced chondrogenesis in articular cartilage (<xref ref-type="bibr" rid="B25">25</xref>) and is a potential regulator of collagen mineralization (<xref ref-type="bibr" rid="B26">26</xref>). Finally, the Western blots for periostin and asporin were analyzed by densitometry, and the densitometry values were correlated with the spectral counts obtained from the RePlay analysis (<italic>n</italic> = 2, mean Â± S.D.) (<xref ref-type="fig" rid="F5">Fig. 5</xref>, <italic>C</italic> and <italic>D</italic>). Although the technical replicates obtained using the RePlay device were accurate, there is expected variability in the different clinical samples. Representative MS/MS spectra for periostin and asporin are shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 4, B and C</ext-link>.</p></sec><sec><title>Proteolysis</title><p>Finally, we investigated whether the NaCl extract represents a subproteome enriched in degradation products. Currently, our understanding of ECM proteolysis is based on <italic>in vitro</italic> experiments, which do not necessarily relate to <italic>in vivo</italic> processes. In our methodology, the original molecular mass distribution of the identified proteins is preserved by the gel LC-MS/MS approach. Thus, our method can be important for advancing our understanding of protein degradation <italic>in vivo</italic>. For instance, we noted that in a fourth aortic specimen, which was classified as normal upon aortotomy, the coefficient of variation for the number of fibronectin spectra in the NaCl extract exceeded 100%, implying a significant difference in the dispersion of the data among the analyzed samples (<italic>p</italic> ANOVA &lt;0.05). On the other hand, the coefficient of variation for samples 1â3 is not significant (58%; <italic>p</italic> ANOVA &gt;0.05). We also noted that there was an increase in fibronectin sequence coverage (<xref ref-type="fig" rid="F6">Fig. 6</xref>, <italic>A</italic> and <italic>B</italic>) and total fibronectin spectra (â¼4-fold) in the NaCl extract of the fourth specimen. Closer inspection of the molecular mass distribution of fibronectin spectra indicated the breakdown of fibronectin in this particular sample with more than 80% of fibronectin spectra identified in gel bands below 150 kDa. Western blotting using an antibody raised against full-length human fibronectin confirmed extensive laddering of the glycoprotein in both the NaCl and guanidine extracts (<xref ref-type="fig" rid="F6">Fig. 6</xref>, <italic>C</italic> and <italic>D</italic>). Fibronectin degradation products have been implicated in the induction of proinflammatory responses in the vasculature and other tissues (<xref ref-type="bibr" rid="B1">1</xref>). Interestingly, mass spectrometry provided spectral evidence for MMP-9 only in this particular sample (<xref ref-type="fig" rid="F6">Fig. 6</xref><italic>E</italic>), and the presence of MMP-9 was confirmed by gelatin zymography (<xref ref-type="fig" rid="F6">Fig. 6</xref><italic>C</italic>, <italic>lower panel</italic>). Fibronectin is a known substrate for MMP-9 (<xref ref-type="bibr" rid="B27">27</xref>), but obviously, we cannot exclude that other proteinases contribute to the breakdown of fibronectin in this specimen <italic>in vivo</italic>. The example, however, demonstrates the potential of our methodology to analyze proteolytic activity based on the presence of proteolytic enzymes and corresponding degradation products in tissues. Importantly, this key information on protein breakdown within clinical samples that were considered normal macroscopically could be lost by using a conventional shotgun proteomics approach.</p><fig id="F6" position="float"><label>Fig. 6.</label><caption><p><bold>Detection of proteolysis.</bold> Percent sequence coverage for fibronectin in the NaCl (<italic>A</italic>) and guanidine extracts (<italic>B</italic>) is shown. â<italic>R</italic>â denotes RePlay analysis. Note the increase of fibronectin products in the NaCl extracts of the fourth aortic specimen. Western immunoblotting of fibronectin in the NaCl (<italic>C</italic>) and guanidine (<italic>D</italic>) extracts confirmed the laddering of fibronectin. The product ion spectrum of the doubly charged tryptic peptide SLGPALLLLQK was identified as MMP-9 (<italic>E</italic>) (peptide probability, 95%; SEQUEST XCorr score, 2.67; SEQUEST ÎCn score, 0.40; observed <italic>m</italic>/<italic>z</italic>, 576.87; actual peptide mass, 1,151.73 Da; peptide charge, 2; delta amu, 0.0049; delta ppm, 4.3; peptide start index, 66; peptide stop index, 76). MMP-9 was only detected by LC-MS/MS in the NaCl extract of the fourth aortic specimen. Gelatin zymography confirmed higher levels of MMP-9 in this sample (<italic>C</italic>, <italic>bottom panel</italic>).</p></caption><graphic xlink:href="zjw0091036770006"/></fig></sec></sec></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study, we combined biochemical fractionation with proteomics to comprehensively characterize the protein composition of the vascular extracellular environment. The main advantage of our methodology is the stepwise approach, which results in the isolation of proteins and protein degradation products loosely bound to the ECM in the NaCl fraction, the depletion of cellular proteins in the SDS fraction, and the effective solubilization of ECM proteins in the guanidine fraction.</p><sec><title/><sec><title/><sec><title>Comprehensive Matrix Analysis</title><p>Until now, a comprehensive analysis of extracellular space components comprising the vascular proteome in humans has not been performed. Previous attempts to utilize the analytical power of proteomics to study ECM components and associated proteins have been limited by the fact that without prefractionation cellular and plasma proteins in mammalian tissues overwhelm the analytical capacities of the instruments and obscure the identification of scarce proteins in the extracellular environment. Therefore, it is not surprising that all extracellular space proteins found in the SDS extracts (except from type XIV collagen) have been reported before by proteomics studies of different vascular tissues.</p><p>On the other hand, the tissue subfractionation resulted in the identification of numerous proteins in the NaCl and guanidine extracts, which have not been investigated in the vasculature until now. The relative insolubility and the extensive post-translational modifications, especially glycosylation, render ECM proteins difficult to analyze. For example, we identified and validated the presence of three glycoproteins: podocan, originally described as a glycoprotein secreted by kidney podocytes; sclerostin, another small glycoprotein, which has recently received attention because of its ability to act as a potent negative regulator of bone morphogenetic protein signaling and bone mineralization; and agrin, a large basement membrane proteoglycan, which participates in the organization of the synapses in the neuromuscular junction. We also identified and validated the presence of the atypical proteoglycan asporin in our aortic extracts.</p><p>Moreover, the NaCl and guanidine extracts contained two ECM glycoproteins, tenascin-X and AEBP1. The first is believed to be a modulator of collagen fibrillogenesis (<xref ref-type="bibr" rid="B28">28</xref>). Interestingly, genetic deletion of tenascin-X in mice resulted in increased activity of MMP-2 and -9 (<xref ref-type="bibr" rid="B29">29</xref>). Less is known about AEBP1; the extracellular isoform was originally found to play a role in wound healing (<xref ref-type="bibr" rid="B30">30</xref>), and more recently, Majdalawieh <italic>et al.</italic> (<xref ref-type="bibr" rid="B31">31</xref>) showed that intracellular AEBP1 represses macrophage cholesterol efflux.</p><p>Among collagens, collagen VI appears to be very abundant in our extracts. It serves mainly as a substrate for the attachment of cells and matrix molecules and also anchors basement membranes to underlying connective tissues (<xref ref-type="bibr" rid="B32">32</xref>). More interesting, however, is the identification of type XIV collagen (<xref ref-type="bibr" rid="B33">33</xref>). Previous proteomics studies probably failed to identify this collagen because it is heavily modified by chondroitin sulfate saccharides <italic>in vivo</italic> (<xref ref-type="bibr" rid="B34">34</xref>). These modifications greatly increase its size and alter its electrophoretic properties but are removed by the deglycosylation step in our extraction methodology.</p><p>Finally, many scarce proteins, including LIM and cysteine-rich domains protein 1 (LMCD1), target of Nesh-SH3 (TARSH), and RPE-spondin (a previously hypothetical protein (<xref ref-type="bibr" rid="B35">35</xref>)), were all identified for the first time by proteomics in the vasculature, and representative MS/MS spectra are shown in <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Fig. 5</ext-link>. Their function in the vasculature is unknown.</p><p>The subfractionation presented here could be an important tool for studying catabolic processes in tissues. In the NaCl fraction, we found fibronectin degradation products and the presence of MMP-2 and -9 as verified by gelatinolytic zymography. Mass spectrometry also identified two mast cell proteases, namely chymase and tryptase Î²-1. The first was recently found to participate in the development of mouse abdominal aneurysm (<xref ref-type="bibr" rid="B36">36</xref>), whereas the second, an activator of MMP-3 (<xref ref-type="bibr" rid="B37">37</xref>), has been shown to degrade the antiatherogenic high density lipoprotein (HDL) (<xref ref-type="bibr" rid="B38">38</xref>). Their presence in the aortic extracts might suggest an early involvement of mast cells in aortic pathology (<xref ref-type="bibr" rid="B39">39</xref>).</p></sec><sec><title>Application to Clinical Samples</title><p>As far as vascular research is concerned, the methodical and accurate characterization of the vascular extracellular environment is essential to advance our understanding of the ECM composition in different vascular territories and their predisposition to disease processes. For instance, atherosclerosis, the major cause for morbidity and mortality in the developed world, is intimately related to dynamic changes in the ECM and its associated proteins: the retention of lipoproteins by proteoglycans leads to the development of atherosclerotic lesions, but ultimately, it is the breakdown of ECM that facilitates plaque ruptures, triggering the onset of clinical symptoms. These changes, if comprehensively characterized, could lead to new therapeutic options for cardiovascular disease. Finally, because metabolic labeling cannot be used with clinical samples, spectral counting is an alternative method to assess relative protein abundance (<xref ref-type="bibr" rid="B40">40</xref>), but its accuracy is poor for proteins with low spectral counts (<xref ref-type="bibr" rid="B41">41</xref>).</p><p>In conclusion, the proteomics method described allowed (<italic>a</italic>) the identification of scarce proteins present in the vascular extracellular space, (<italic>b</italic>) the identification of novel glycoproteins, and (<italic>c</italic>) the interrogation of proteolytic activity within tissues based on the identification of proteolytic enzymes and corresponding degradation products. Because ECM proteins accumulate in tissues, mRNA transcripts do not correspond to actual protein levels. In contrast, a proteomics-led approach has the potential to provide a more comprehensive analysis of the ECM composition and shed new light on pathological disease processes.</p></sec></sec></sec></sec>
      <sec sec-type="supplementary-material">
         <title>Supplementary Material</title>
         <supplementary-material id="PMC_1" content-type="local-data">
            <caption>
               <title>Supplemental Data</title>
            </caption>
            <media mimetype="text" mime-subtype="html" xlink:href="supp_9_9_2048__index.html"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_M110.001693_mcp.M110.001693-2.pdf"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_M110.001693_mcp.M110.001693-3.pdf"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_M110.001693_mcp.M110.001693-1.pdf"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_M110.001693_mcp.M110.001693-4.pdf"/>
         </supplementary-material>
      </sec>
   </body>
  <back>
    <fn-group>
      <fn id="FN1" fn-type="supported-by">
        <p>* This work was supported in part by grants from the Oak Foundation and the British Heart Foundation.</p>
      </fn>
      <fn fn-type="supplementary-material" id="FN2">
        <p><sup><inline-graphic xlink:href="sbox.jpg"/></sup> This article contains <ext-link ext-link-type="uri" xlink:href="http://www.mcponline.org/cgi/content/full/M110.001693/DC1">supplemental Figs. 1â5 and Tables 1â3</ext-link>.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn id="G1" fn-type="abbr">
        <p><sup>1</sup> The abbreviations used are:</p>
        <p>
<def-list><def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item><def-item><term>MMP</term><def><p>matrix metalloproteinase</p></def></def-item><def-item><term>GAG</term><def><p>glycosaminoglycan</p></def></def-item><def-item><term>Bis-Tris</term><def><p>2-[bis(2- hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>AEBP1</term><def><p>adipocyte enhancer-binding protein 1</p></def></def-item><def-item><term>RPE</term><def><p>retinal pigment epithelium</p></def></def-item><def-item><term>LTQ</term><def><p>linear trap quadrupole.</p></def></def-item></def-list></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didangelos</surname><given-names>A.</given-names></name><name><surname>Simper</surname><given-names>D.</given-names></name><name><surname>Monaco</surname><given-names>C.</given-names></name><name><surname>Mayr</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>) <article-title>Proteomics of acute coronary syndromes</article-title>. <source>Curr. Atheroscler. Rep</source>. <volume>11</volume>, <fpage>188</fpage>â<lpage>195</lpage><pub-id pub-id-type="pmid">19361350</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talusan</surname><given-names>P.</given-names></name><name><surname>Bedri</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Kattapuram</surname><given-names>T.</given-names></name><name><surname>Silva</surname><given-names>N.</given-names></name><name><surname>Roughley</surname><given-names>P. J.</given-names></name><name><surname>Stone</surname><given-names>J. R.</given-names></name></person-group> (<year>2005</year>) <article-title>Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry</article-title>. <source>Mol. Cell. Proteomics</source><volume>4</volume>, <fpage>1350</fpage>â<lpage>1357</lpage><pub-id pub-id-type="pmid">15970583</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>M.</given-names></name><name><surname>Chung</surname><given-names>Y. L.</given-names></name><name><surname>Mayr</surname><given-names>U.</given-names></name><name><surname>Yin</surname><given-names>X.</given-names></name><name><surname>Ly</surname><given-names>L.</given-names></name><name><surname>Troy</surname><given-names>H.</given-names></name><name><surname>Fredericks</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Griffiths</surname><given-names>J. R.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2005</year>) <article-title>Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism</article-title>. <source>Arterioscler. Thromb. Vasc. Biol</source>. <volume>25</volume>, <fpage>2135</fpage>â<lpage>2142</lpage><pub-id pub-id-type="pmid">16123314</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>M.</given-names></name><name><surname>Zampetaki</surname><given-names>A.</given-names></name><name><surname>Sidibe</surname><given-names>A.</given-names></name><name><surname>Mayr</surname><given-names>U.</given-names></name><name><surname>Yin</surname><given-names>X.</given-names></name><name><surname>De Souza</surname><given-names>A. I.</given-names></name><name><surname>Chung</surname><given-names>Y. L.</given-names></name><name><surname>Madhu</surname><given-names>B.</given-names></name><name><surname>Quax</surname><given-names>P. H.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Griffiths</surname><given-names>J. R.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2008</year>) <article-title>Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice</article-title>. <source>Circ. Res</source>. <volume>102</volume>, <fpage>1046</fpage>â<lpage>1056</lpage><pub-id pub-id-type="pmid">18388323</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Sousa</surname><given-names>E.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Pittman</surname><given-names>D. D.</given-names></name><name><surname>Maganti</surname><given-names>V.</given-names></name><name><surname>Feldman</surname><given-names>J.</given-names></name><name><surname>Gill</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Dorner</surname><given-names>A. J.</given-names></name><name><surname>Schaub</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>X. Y.</given-names></name></person-group> (<year>2007</year>) <article-title>Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion</article-title>. <source>J. Proteome Res</source>. <volume>6</volume>, <fpage>4728</fpage>â<lpage>4736</lpage><pub-id pub-id-type="pmid">17997517</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenstein</surname><given-names>R.</given-names></name><name><surname>Larsson</surname><given-names>S. E.</given-names></name><name><surname>Kuettner</surname><given-names>K. E.</given-names></name><name><surname>Sorgente</surname><given-names>N.</given-names></name><name><surname>Hascal</surname><given-names>V. C.</given-names></name></person-group> (<year>1975</year>) <article-title>The ground substance of the arterial wall. Part 1. Extractability of glycosaminoglycans and the isolation of a proteoglycan from bovine aorta</article-title>. <source>Atherosclerosis</source><volume>22</volume>, <fpage>1</fpage>â<lpage>17</lpage><pub-id pub-id-type="pmid">125595</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>F.</given-names></name><name><surname>Li-Ling</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2003</year>) <article-title>Comparative analysis of amino acid usage and protein length distribution between alternatively and non-alternatively spliced genes across six eukaryotic genomes</article-title>. <source>Mol. Biol. Evol</source>. <volume>20</volume>, <fpage>1978</fpage>â<lpage>1985</lpage><pub-id pub-id-type="pmid">12885959</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waanders</surname><given-names>L. F.</given-names></name><name><surname>Almeida</surname><given-names>R.</given-names></name><name><surname>Prosser</surname><given-names>S.</given-names></name><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Eikel</surname><given-names>D.</given-names></name><name><surname>Allen</surname><given-names>M. H.</given-names></name><name><surname>Schultz</surname><given-names>G. A.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>) <article-title>A novel chromatographic method allows on-line reanalysis of the proteome</article-title>. <source>Mol. Cell. Proteomics</source><volume>7</volume>, <fpage>1452</fpage>â<lpage>1459</lpage><pub-id pub-id-type="pmid">18448420</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name><name><surname>Kolker</surname><given-names>E.</given-names></name><name><surname>Aebersold</surname><given-names>R.</given-names></name></person-group> (<year>2002</year>) <article-title>Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search</article-title>. <source>Anal. Chem</source>. <volume>74</volume>, <fpage>5383</fpage>â<lpage>5392</lpage><pub-id pub-id-type="pmid">12403597</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Kolker</surname><given-names>E.</given-names></name><name><surname>Aebersold</surname><given-names>R.</given-names></name></person-group> (<year>2003</year>) <article-title>A statistical model for identifying proteins by tandem mass spectrometry</article-title>. <source>Anal. Chem</source>. <volume>75</volume>, <fpage>4646</fpage>â<lpage>4658</lpage><pub-id pub-id-type="pmid">14632076</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groves</surname><given-names>W. E.</given-names></name><name><surname>Davis</surname><given-names>F. C.</given-names><suffix>Jr.</suffix></name><name><surname>Sells</surname><given-names>B. H.</given-names></name></person-group> (<year>1968</year>) <article-title>Spectrophotometric determination of microgram quantities of protein without nucleic acid interference</article-title>. <source>Anal. Biochem</source>. <volume>22</volume>, <fpage>195</fpage>â<lpage>210</lpage><pub-id pub-id-type="pmid">4171014</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>R. M.</given-names></name><name><surname>Mayes</surname><given-names>R. W.</given-names></name></person-group> (<year>1973</year>) <article-title>Extraction of cartilage protein-polysaccharides with inorganic salt solutions</article-title>. <source>Biochem. J</source>. <volume>131</volume>, <fpage>535</fpage>â<lpage>540</lpage><pub-id pub-id-type="pmid">4269048</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>S. L.</given-names></name><name><surname>Koh</surname><given-names>J.</given-names></name><name><surname>Prabhakar</surname><given-names>V.</given-names></name><name><surname>Niklason</surname><given-names>L. E.</given-names></name></person-group> (<year>2003</year>) <article-title>Decellularized native and engineered arterial scaffolds for transplantation</article-title>. <source>Cell Transplant</source>. <volume>12</volume>, <fpage>659</fpage>â<lpage>666</lpage><pub-id pub-id-type="pmid">14579934</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korossis</surname><given-names>S. A.</given-names></name><name><surname>Wilcox</surname><given-names>H. E.</given-names></name><name><surname>Watterson</surname><given-names>K. G.</given-names></name><name><surname>Kearney</surname><given-names>J. N.</given-names></name><name><surname>Ingham</surname><given-names>E.</given-names></name><name><surname>Fisher</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>) <article-title>In-vitro assessment of the functional performance of the decellularized intact porcine aortic root</article-title>. <source>J. Heart Valve Dis</source>. <volume>14</volume>, <fpage>408</fpage>â<lpage>422</lpage><pub-id pub-id-type="pmid">15974537</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>T. W.</given-names></name><name><surname>Sellaro</surname><given-names>T. L.</given-names></name><name><surname>Badylak</surname><given-names>S. F.</given-names></name></person-group> (<year>2006</year>) <article-title>Decellularization of tissues and organs</article-title>. <source>Biomaterials</source><volume>27</volume>, <fpage>3675</fpage>â<lpage>3683</lpage><pub-id pub-id-type="pmid">16519932</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izano</surname><given-names>E. A.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ragunath</surname><given-names>C.</given-names></name><name><surname>Ramasubbu</surname><given-names>N.</given-names></name><name><surname>Kaplan</surname><given-names>J. B.</given-names></name></person-group> (<year>2007</year>) <article-title>Detachment and killing of Aggregatibacter actinomycetemcomitans biofilms by dispersin B and SDS</article-title>. <source>J. Dent. Res</source>. <volume>86</volume>, <fpage>618</fpage>â<lpage>622</lpage><pub-id pub-id-type="pmid">17586707</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>A.</given-names></name><name><surname>Ziegler</surname><given-names>A.</given-names></name><name><surname>Steinbauer</surname><given-names>B.</given-names></name><name><surname>Seelig</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>) <article-title>Thermodynamics of sodium dodecyl sulfate partitioning into lipid membranes</article-title>. <source>Biophys. J</source>. <volume>83</volume>, <fpage>1547</fpage>â<lpage>1556</lpage><pub-id pub-id-type="pmid">12202379</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajdera</surname><given-names>S. W.</given-names></name><name><surname>Hascall</surname><given-names>V. C.</given-names></name></person-group> (<year>1969</year>) <article-title>Proteinpolysaccharide complex from bovine nasal cartilage. A comparison of low and high shear extraction procedures</article-title>. <source>J. Biol. Chem</source>. <volume>244</volume>, <fpage>77</fpage>â<lpage>87</lpage><pub-id pub-id-type="pmid">4237578</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>M. D.</given-names></name><name><surname>Bruggeman</surname><given-names>L. A.</given-names></name><name><surname>Hanss</surname><given-names>B.</given-names></name><name><surname>Sunamoto</surname><given-names>M.</given-names></name><name><surname>Marras</surname><given-names>D.</given-names></name><name><surname>Klotman</surname><given-names>M. E.</given-names></name><name><surname>Klotman</surname><given-names>P. E.</given-names></name></person-group> (<year>2003</year>) <article-title>Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy</article-title>. <source>J. Biol. Chem</source>. <volume>278</volume>, <fpage>33248</fpage>â<lpage>33255</lpage><pub-id pub-id-type="pmid">12796502</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>M. K.</given-names></name><name><surname>Geoghegan</surname><given-names>J. C.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Turcott</surname><given-names>E.</given-names></name><name><surname>Skonier</surname><given-names>J. E.</given-names></name><name><surname>Winkler</surname><given-names>D. G.</given-names></name><name><surname>Latham</surname><given-names>J. A.</given-names></name></person-group> (<year>2004</year>) <article-title>Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation</article-title>. <source>Bone</source><volume>35</volume>, <fpage>828</fpage>â<lpage>835</lpage><pub-id pub-id-type="pmid">15454089</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>S. T.</given-names></name><name><surname>Noakes</surname><given-names>P. G.</given-names></name><name><surname>Phillips</surname><given-names>W. D.</given-names></name></person-group> (<year>2007</year>) <article-title>Neural agrin: a synaptic stabiliser</article-title>. <source>Int. J. Biochem. Cell Biol</source>. <volume>39</volume>, <fpage>863</fpage>â<lpage>867</lpage><pub-id pub-id-type="pmid">17126587</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segev</surname><given-names>A.</given-names></name><name><surname>Nili</surname><given-names>N.</given-names></name><name><surname>Strauss</surname><given-names>B. H.</given-names></name></person-group> (<year>2004</year>) <article-title>The role of perlecan in arterial injury and angiogenesis</article-title>. <source>Cardiovasc. Res</source>. <volume>63</volume>, <fpage>603</fpage>â<lpage>610</lpage><pub-id pub-id-type="pmid">15306215</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bregant</surname><given-names>S.</given-names></name><name><surname>Huillet</surname><given-names>C.</given-names></name><name><surname>Devel</surname><given-names>L.</given-names></name><name><surname>Dabert-Gay</surname><given-names>A. S.</given-names></name><name><surname>Beau</surname><given-names>F.</given-names></name><name><surname>Thai</surname><given-names>R.</given-names></name><name><surname>Czarny</surname><given-names>B.</given-names></name><name><surname>Yiotakis</surname><given-names>A.</given-names></name><name><surname>Dive</surname><given-names>V.</given-names></name></person-group> (<year>2009</year>) <article-title>Detection of matrix metalloproteinase active forms in complex proteomes: evaluation of affinity versus photoaffinity capture</article-title>. <source>J. Proteome Res</source>. <volume>8</volume>, <fpage>2484</fpage>â<lpage>2494</lpage><pub-id pub-id-type="pmid">19271733</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindner</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Conley</surname><given-names>B. A.</given-names></name><name><surname>Friesel</surname><given-names>R. E.</given-names></name><name><surname>Vary</surname><given-names>C. P.</given-names></name></person-group> (<year>2005</year>) <article-title>Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration</article-title>. <source>Arterioscler. Thromb. Vasc. Biol</source>. <volume>25</volume>, <fpage>77</fpage>â<lpage>83</lpage><pub-id pub-id-type="pmid">15514205</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Kizawa</surname><given-names>H.</given-names></name><name><surname>Saitoh</surname><given-names>M.</given-names></name><name><surname>Kou</surname><given-names>I.</given-names></name><name><surname>Miyazono</surname><given-names>K.</given-names></name><name><surname>Ikegawa</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>) <article-title>Mechanisms for asporin function and regulation in articular cartilage</article-title>. <source>J. Biol. Chem</source>. <volume>282</volume>, <fpage>32185</fpage>â<lpage>32192</lpage><pub-id pub-id-type="pmid">17827158</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalamajski</surname><given-names>S.</given-names></name><name><surname>Aspberg</surname><given-names>A.</given-names></name><name><surname>Lindblom</surname><given-names>K.</given-names></name><name><surname>HeinegÃ¥rd</surname><given-names>D.</given-names></name><name><surname>Oldberg</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>) <article-title>Asporin competes with decorin for collagen binding, binds calcium and promotes osteoblast collagen mineralization</article-title>. <source>Biochem. J</source>. <volume>423</volume>, <fpage>53</fpage>â<lpage>59</lpage><pub-id pub-id-type="pmid">19589127</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram</surname><given-names>M.</given-names></name><name><surname>Sherer</surname><given-names>Y.</given-names></name><name><surname>Shoenfeld</surname><given-names>Y.</given-names></name></person-group> (<year>2006</year>) <article-title>Matrix metalloproteinase-9 and autoimmune diseases</article-title>. <source>J. Clin. Immunol</source>. <volume>26</volume>, <fpage>299</fpage>â<lpage>307</lpage><pub-id pub-id-type="pmid">16652230</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J. R.</given-names></name><name><surname>Taylor</surname><given-names>G.</given-names></name><name><surname>Dean</surname><given-names>W. B.</given-names></name><name><surname>Wagner</surname><given-names>D. R.</given-names></name><name><surname>Afzal</surname><given-names>V.</given-names></name><name><surname>Lotz</surname><given-names>J. C.</given-names></name><name><surname>Rubin</surname><given-names>E. M.</given-names></name><name><surname>Bristow</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>) <article-title>Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition</article-title>. <source>Nat. Genet</source>. <volume>30</volume>, <fpage>421</fpage>â<lpage>425</lpage><pub-id pub-id-type="pmid">11925569</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Takayama</surname><given-names>N.</given-names></name><name><surname>Ohnishi</surname><given-names>J.</given-names></name><name><surname>Ohnishi</surname><given-names>E.</given-names></name><name><surname>Shirayoshi</surname><given-names>Y.</given-names></name><name><surname>Nakatsuji</surname><given-names>N.</given-names></name><name><surname>Ariga</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>) <article-title>Tumour invasion and metastasis are promoted in mice deficient in tenascin-X</article-title>. <source>Genes Cells</source><volume>6</volume>, <fpage>1101</fpage>â<lpage>1111</lpage><pub-id pub-id-type="pmid">11737270</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layne</surname><given-names>M. D.</given-names></name><name><surname>Yet</surname><given-names>S. F.</given-names></name><name><surname>Maemura</surname><given-names>K.</given-names></name><name><surname>Hsieh</surname><given-names>C. M.</given-names></name><name><surname>Bernfield</surname><given-names>M.</given-names></name><name><surname>Perrella</surname><given-names>M. A.</given-names></name><name><surname>Lee</surname><given-names>M. E.</given-names></name></person-group> (<year>2001</year>) <article-title>Impaired abdominal wall development and deficient wound healing in mice lacking aortic carboxypeptidase-like protein</article-title>. <source>Mol. Cell. Biol</source>. <volume>21</volume>, <fpage>5256</fpage>â<lpage>5261</lpage><pub-id pub-id-type="pmid">11438679</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majdalawieh</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fuki</surname><given-names>I. V.</given-names></name><name><surname>Rader</surname><given-names>D. J.</given-names></name><name><surname>Ro</surname><given-names>H. S.</given-names></name></person-group> (<year>2006</year>) <article-title>Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>103</volume>, <fpage>2346</fpage>â<lpage>2351</lpage><pub-id pub-id-type="pmid">16461908</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampe</surname><given-names>A. K.</given-names></name><name><surname>Bushby</surname><given-names>K. M.</given-names></name></person-group> (<year>2005</year>) <article-title>Collagen VI related muscle disorders</article-title>. <source>J. Med. Genet</source>. <volume>42</volume>, <fpage>673</fpage>â<lpage>685</lpage><pub-id pub-id-type="pmid">16141002</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyre</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>) <article-title>Collagen of articular cartilage</article-title>. <source>Arthritis Res</source>. <volume>4</volume>, <fpage>30</fpage>â<lpage>35</lpage><pub-id pub-id-type="pmid">11879535</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>S. L.</given-names></name><name><surname>Lunstrum</surname><given-names>G. P.</given-names></name><name><surname>McDonough</surname><given-names>A. M.</given-names></name><name><surname>Keene</surname><given-names>D. R.</given-names></name><name><surname>Burgeson</surname><given-names>R. E.</given-names></name><name><surname>Morris</surname><given-names>N. P.</given-names></name></person-group> (<year>1992</year>) <article-title>Characterization of collagen types XII and XIV from fetal bovine cartilage</article-title>. <source>J. Biol. Chem</source>. <volume>267</volume>, <fpage>20093</fpage>â<lpage>20099</lpage><pub-id pub-id-type="pmid">1400327</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>H. L.</given-names></name><name><surname>Rahman</surname><given-names>F. A.</given-names></name><name><surname>Fadl El Moula</surname><given-names>F. M.</given-names></name><name><surname>Stojic</surname><given-names>J.</given-names></name><name><surname>Gehrig</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>B. H.</given-names></name></person-group> (<year>2004</year>) <article-title>Identifying differentially expressed genes in the mammalian retina and the retinal pigment epithelium by suppression subtractive hybridization</article-title>. <source>Cytogenet. Genome Res</source>. <volume>106</volume>, <fpage>74</fpage>â<lpage>81</lpage><pub-id pub-id-type="pmid">15218245</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Lindholt</surname><given-names>J. S.</given-names></name><name><surname>Sukhova</surname><given-names>G. K.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>A.</given-names></name><name><surname>Abrink</surname><given-names>M.</given-names></name><name><surname>Pejler</surname><given-names>G.</given-names></name><name><surname>Stevens</surname><given-names>R. L.</given-names></name><name><surname>Thompson</surname><given-names>R. W.</given-names></name><name><surname>Ennis</surname><given-names>T. L.</given-names></name><name><surname>Gurish</surname><given-names>M. F.</given-names></name><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Shi</surname><given-names>G. P.</given-names></name></person-group> (<year>2009</year>) <article-title>Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation</article-title>. <source>Circulation</source><volume>120</volume>, <fpage>973</fpage>â<lpage>982</lpage><pub-id pub-id-type="pmid">19720934</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deliargyris</surname><given-names>E. N.</given-names></name><name><surname>Upadhya</surname><given-names>B.</given-names></name><name><surname>Sane</surname><given-names>D. C.</given-names></name><name><surname>Dehmer</surname><given-names>G. J.</given-names></name><name><surname>Pye</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>S. C.</given-names><suffix>Jr.</suffix></name><name><surname>Boucher</surname><given-names>W. S.</given-names></name><name><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2005</year>) <article-title>Mast cell tryptase: a new biomarker in patients with stable coronary artery disease</article-title>. <source>Atherosclerosis</source><volume>178</volume>, <fpage>381</fpage>â<lpage>386</lpage><pub-id pub-id-type="pmid">15694948</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Sommerhoff</surname><given-names>C. P.</given-names></name><name><surname>von Eckardstein</surname><given-names>A.</given-names></name><name><surname>Zettl</surname><given-names>F.</given-names></name><name><surname>Fritz</surname><given-names>H.</given-names></name><name><surname>Kovanen</surname><given-names>P. T.</given-names></name></person-group> (<year>2002</year>) <article-title>Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol</article-title>. <source>Arterioscler. Thromb. Vasc. Biol</source>. <volume>22</volume>, <fpage>2086</fpage>â<lpage>2091</lpage><pub-id pub-id-type="pmid">12482839</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzler</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>1997</year>) <article-title>The role of mast cells in atherosclerosis</article-title>. <source>Int. Arch. Allergy Immunol</source>. <volume>114</volume>, <fpage>10</fpage>â<lpage>14</lpage><pub-id pub-id-type="pmid">9303325</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Sadygov</surname><given-names>R. G.</given-names></name><name><surname>Yates</surname><given-names>J. R.</given-names><suffix>3rd</suffix></name></person-group> (<year>2004</year>) <article-title>A model for random sampling and estimation of relative protein abundance in shotgun proteomics</article-title>. <source>Anal. Chem</source>. <volume>76</volume>, <fpage>4193</fpage>â<lpage>4201</lpage><pub-id pub-id-type="pmid">15253663</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Old</surname><given-names>W. M.</given-names></name><name><surname>Meyer-Arendt</surname><given-names>K.</given-names></name><name><surname>Aveline-Wolf</surname><given-names>L.</given-names></name><name><surname>Pierce</surname><given-names>K. G.</given-names></name><name><surname>Mendoza</surname><given-names>A.</given-names></name><name><surname>Sevinsky</surname><given-names>J. R.</given-names></name><name><surname>Resing</surname><given-names>K. A.</given-names></name><name><surname>Ahn</surname><given-names>N. G.</given-names></name></person-group> (<year>2005</year>) <article-title>Comparison of label-free methods for quantifying human proteins by shotgun proteomics</article-title>. <source>Mol. Cell. Proteomics</source><volume>4</volume>, <fpage>1487</fpage>â<lpage>1502</lpage><pub-id pub-id-type="pmid">15979981</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>